Galectin-1 overexpression promotes cisplatin resistance in ovarian cancer cells and doxorubicin resistance in triple-negative breast cancer cells [13, 14], indicating the association of Galectin-1 signal transduction with cancer drug resistance. This evidence concerns the gene LGALS1 and triple-negative breast carcinoma.